Palantir's Defense Backlog Holds Firm as Civilian Rollout Hits Turbulence

Palantir holds a $48M Army ammunition contract and other public-sector wins, but Goldman stays Neutral as UK health-data objections mount.

Palantir's government business continues to churn out contracts at a steady clip, yet the company's push into civilian and overseas markets is meeting resistance that Wall Street has yet to fully price in.

The stock finished yesterday's session at €168.80, leaving it 6.2% below its 52-week high of €179.98. During today's trading, the shares edged up 0.7%, though they have gained 2.3% since calls for contract cancellations intensified roughly a week ago.

A $48 Million Anchor at the Pentagon

The bedrock of Palantir's model remains long-term public-sector work. On September 17, subsidiary Palantir USG locked in a fixed-price delivery order from the U.S. Army worth $48,094,071 to modernize ammunition management, carrying a twelve-month base term with multi-year extension options. The system is designed to consolidate and retire nine legacy military platforms in one sweep.

That award underscores how entrenched the company has become when complex legacy systems need replacing with modern data architectures. The demand isn't confined to the Pentagon, either. The U.S. Department of Agriculture handed over $856,668.56 for a financial audit tool, while the National Center for Advancing Translational Sciences issued a task order for a cloud-based research environment capped at $9,738,016. Smaller in isolation, these projects nonetheless reinforce the public-sector foundation.

Product development has kept pace. Beyond configuration tweaks to AIP Analyst, Palantir rolled out additional Foundry capabilities in early October. On the sensitive-infrastructure front, Armada now operates as the first certified partner for modular data centers — financial terms of that arrangement were not disclosed.

Goldman Stays on the Sidelines

Institutional observers, however, are showing little appetite for chasing the stock. On September 28, Goldman Sachs analyst Gabriela Borges reaffirmed her "Neutral" rating with a $204 price target, following a meeting with CFO Dave Glazer that covered Palantir's deployment model and how it differentiates itself from rivals. The reluctance of a major house to issue a buy recommendation despite solid operational momentum speaks to concerns about how much growth is already baked into the valuation.

European Friction Over Health Data

International expansion is proving anything but smooth. Medical staff and activists in the U.K. demonstrated roughly a week ago against Palantir's role in the National Health Service, raising patient-data concerns. According to The Guardian, more than 44,000 citizens have filed legal objections to the sharing of their health records, with the objections targeting the NHS Federated Data Platform, which is built on Palantir technology.

The episode illustrates how quickly technology can run into public opposition when it touches civilian healthcare — a reminder that the company must still earn its valuation premium in commercial and international arenas.

Executive Share Allotments

On the leadership front, filings with the SEC dated October 1 show that executives Jeffrey Buckley, Ryan D. Taylor and David A. Glazer received share allotments tied to transactions from September 29.

All told, Palantir stands on solid operational ground. Its broad embedding across U.S. agencies generates dependable revenue that shields it from abrupt shocks, and the long-term case rests on the ongoing digitization of government and administrative processes. Near term, though, Goldman's neutral stance points to a consolidation phase until the company can demonstrate a frictionless expansion across Europe and the private sector.